Literature DB >> 8594316

Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin.

D Gully1, L Lespy, M Canton, W Rostène, P Kitabgi, G Le Fur, J P Maffrand.   

Abstract

When administered as an intravenous injection in the pentobarbitone-anaesthetized rat, neurotensin (NT) elicits a biphasic depressor-pressor effect that can be evaluated by the mean arterial blood pressure (MABP). The first hypotensive phase elicited by low doses of NT is dependent on the interaction of NT with its specific receptors and may be mediated by the release of histamine, since it is prevented by oral pretreatment with the selective NT receptor antagonist SR 48692 and by intravenous pretreatment with a selective H1 receptor antagonist mepyramine. The hypertensive effect evoked by higher doses of NT is histamine-independent but remains NT receptor- mediated. The prevention of the biphasic effect on MABP by oral administration of the NT receptor antagonist SR 48692 validates the implication of NT receptors in the histamine release phenomenon.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8594316     DOI: 10.1016/s0024-3205(96)80005-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Intrathecal neurotensin is hypotensive, sympathoinhibitory and enhances the baroreflex in anaesthetized rat.

Authors:  B Zogovic; P M Pilowsky
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.

Authors:  James B Thomas; Angela M Giddings; Robert W Wiethe; Srinivas Olepu; Keith R Warner; Philippe Sarret; Louis Gendron; Jean-Michel Longpre; Yanan Zhang; Scott P Runyon; Brian P Gilmour
Journal:  J Med Chem       Date:  2014-06-05       Impact factor: 7.446

3.  Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Authors:  Zherui Wu; Daniel Martinez-Fong; Jean Trédaniel; Patricia Forgez
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-17       Impact factor: 5.555

4.  Activation of ventral tegmental area neurotensin Receptor-1 neurons promotes weight loss.

Authors:  Patricia Perez-Bonilla; Krystal Santiago-Colon; Jillian Matasovsky; Jariel Ramirez-Virella; Rabail Khan; Hannah Garver; Gregory Fink; Anne M Dorrance; Gina M Leinninger
Journal:  Neuropharmacology       Date:  2021-06-09       Impact factor: 5.273

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.